Experienced in Pancreaticoduodenectomy

Dr. Jason E. Faris

Oncology
One Medical Center Dr, Dartmouth Hitchcock - Hamatolog/oncology, 
Lebanon, NH 
Experienced in Pancreaticoduodenectomy
One Medical Center Dr, Dartmouth Hitchcock - Hamatolog/oncology, 
Lebanon, NH 
OverviewInsuranceLocationsClinical Research

Overview

Jason Faris is an Oncologist in Lebanon, New Hampshire. Dr. Faris is rated as an Experienced provider by MediFind in Pancreaticoduodenectomy. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Tissue Biopsy, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pancreaticoduodenectomy.

Specialties
Oncology
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO

Locations

One Medical Center Dr, Dartmouth Hitchcock - Hamatolog/oncology, Lebanon, NH 03756
Other Locations
55 Fruit St, Yawkey 7, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors
Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drug: Ziv-Aflibercept
Study Phase: Phase 2
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 08, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

30 Total Publications

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Journal: Nature cancer
Published: June 17, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Faris's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile